Identification | Back Directory | [Name]
(S)-2-(4-chlorophenyl)-3,3-diMethyl-N-(5-phenylthiazol-2-yl)butanaMide | [CAS]
1208552-99-1 | [Synonyms]
CFMB FFAR2 agonist 58 (S)-2-(4-chlorophenyl)-3,3-diMethyl-N-(5-phenylthiazol-2-yl)butanaMide (2S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenyl-1,3-thiazol-2-yl)butanamide Benzeneacetamide, 4-chloro-α-(1,1-dimethylethyl)-N-(5-phenyl-2-thiazolyl)-, (αS)- | [Molecular Formula]
C21H21ClN2OS | [MDL Number]
MFCD22419579 | [MOL File]
1208552-99-1.mol | [Molecular Weight]
384.92 |
Chemical Properties | Back Directory | [density ]
1.241±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 50mg/mL | [form ]
solid | [pka]
8.81±0.50(Predicted) | [color ]
white |
Hazard Information | Back Directory | [Uses]
CFMB is a full agonist of FFAR2- and FFAR3-specific with EC50 value of 0.8 μM target hFFAR2 and 0.2 μM target rFFAR2[1]. | [References]
[1] Charlotte Bayer Christiansen, et al. The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. Am J Physiol Gastrointest Liver Physiol. 2018 Jul 1;315(1):G53-G65. DOI:10.1152/ajpgi.00346.2017 |
|
Company Name: |
Merck KGaA
|
Tel: |
21-20338288 |
Website: |
www.sigmaaldrich.cn |
Company Name: |
Matrix Scientific
|
Tel: |
803 788-9494 All other calls |
Website: |
www.matrixscientific.com |
|